AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 9 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Progenipoietin (ProGP-4) stimulated the proliferation of dendritic cells that have shown effectiveness against cancerous tumors, according to a report in the International Journal of Cancer.
The chimeric molecule progenipoietin (ProGP-4) is a dual receptor agonist for the human FMS-like tyrosine kinase 3 (Flt3) and granulocyte-colony stimulating factor (G-CSF) receptors. Pia Bjorck and colleagues at the University of Pittsburgh and Pharmacia treated BALB/c mice subcutaneously with ProGP-4 (40-100 microgram/day).
The investigators found that the numbers of CD11c+ dendritic cells (DCs) and CD11c-/CD11b+ granulocytes increased significantly in the spleen, blood, and lymph nodes of ProGP-4-treated animals, reaching a peak on the seventh day of treatment. Approximately 8% of splenocytes were CD11c+ DCs, of which almost half could endocytose and present the fluorescent DQ-BSA antigen.
BALB/c mice with 7-day CMS4 sarcomas received two injections (1 week apart) of a vaccine containing either CD11c+ DCs alone or CD11c+ DCs pulsed with a specific murine tumor antigen (murine p53[subscript]232-240). Although the DCs alone did not significantly affect the tumors, the peptide-pulsed DCs caused shrinkage or a reduction in ...